CRUSHMETRIC Group Valuation
Is CUSH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CUSH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CUSH's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CUSH's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CUSH?
Key metric: As CUSH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is CUSH's PS Ratio? | |
|---|---|
| PS Ratio | 42.9x |
| Sales | HK$6.88m |
| Market Cap | HK$295.54m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 45x |
| Enterprise Value/EBITDA | -45.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CUSH's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.6x | ||
TLY Totally | 0.2x | 3.1% | UK£17.2m |
IDHC Integrated Diagnostics Holdings | 2.3x | 19.1% | US$226.7m |
KOO Kooth | 1.1x | 9.4% | UK£60.2m |
GENI GENinCode | 2.8x | n/a | UK£7.3m |
CUSH CRUSHMETRIC Group | 42.8x | n/a | UK£30.0m |
Price-To-Sales vs Peers: CUSH is expensive based on its Price-To-Sales Ratio (42.8x) compared to the peer average (1.6x).
Price to Sales Ratio vs Industry
How does CUSH's PS Ratio compare vs other companies in the European Healthcare Industry?
| 7 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 7 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: CUSH is expensive based on its Price-To-Sales Ratio (42.8x) compared to the European Healthcare industry average (0.6x).
Price to Sales Ratio vs Fair Ratio
What is CUSH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 42.9x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate CUSH's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Fagron
€1.3b
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
0HNZ
€18.33
7D
-2.2%
1Y
6.3%
Guerbet
€334.1m
Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.
0ELV
€26.50
7D
-8.0%
1Y
42.5%
Arjo
SEK 9.0b
Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.
0HQ8
SEK 32.94
7D
-6.2%
1Y
-11.6%